论文部分内容阅读
为了评价长期(3年)使用多沙唑嗪治疗由良性前列腺增生(BPH)所致膀胱出口梗阻的疗效和耐受性,Dutkiewicz S对64名BPH患者进行了治疗观察,并收集了数据。疗效通过尿动力学和症状进行评估。在3年关于多沙唑嗪的随访研究中,排除了放弃治疗和死亡的患者,最后有33名患者一直进行药物治疗,另有11名患者进行了手术治疗。治疗的有效率达75％,25％患者药物治疗失败。多沙唑嗪有良好的耐受性,能使BPH患者的尿动力学指标和症状得到改善。临床试验证实,多沙唑嗪对正常血压的BPH患者和伴有高血压的BPH患者是有效、安全的。
To evaluate the long-term (3 years) efficacy and tolerability of doxazosin in the treatment of BPH-induced bladder outlet obstruction, Dutkiewicz S treated 64 BPH patients and collected data. Efficacy assessed by urodynamic and symptom. In a 3-year follow-up study of doxazosin, patients who had given up their treatment and died were excluded. Finally, 33 patients were treated with medication and 11 others were surgically treated. The effectiveness of treatment was 75%, 25% of patients failed to drug treatment. Doxazosin is well tolerated and can improve urodynamic parameters and symptoms in patients with BPH. Clinical trials confirmed that doxazosin is effective and safe for BPH patients with normotensive and BPH patients with hypertension.